412 related articles for article (PubMed ID: 31903880)
1. Telomere-related Markers for Cancer.
Yuan X; Dai M; Xu D
Curr Top Med Chem; 2020; 20(6):410-432. PubMed ID: 31903880
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players.
Yuan X; Larsson C; Xu D
Oncogene; 2019 Aug; 38(34):6172-6183. PubMed ID: 31285550
[TBL] [Abstract][Full Text] [Related]
3. Crossroads of telomere biology and anticancer drug discovery.
Seimiya H
Cancer Sci; 2020 Sep; 111(9):3089-3099. PubMed ID: 32579791
[TBL] [Abstract][Full Text] [Related]
4. Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies.
Jafri MA; Ansari SA; Alqahtani MH; Shay JW
Genome Med; 2016 Jun; 8(1):69. PubMed ID: 27323951
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and treatment of ALT tumors: is Trabectedin a new therapeutic option?
Pompili L; Leonetti C; Biroccio A; Salvati E
J Exp Clin Cancer Res; 2017 Dec; 36(1):189. PubMed ID: 29273061
[TBL] [Abstract][Full Text] [Related]
6. Potential Telomere-Related Pharmacological Targets.
Berei J; Eckburg A; Miliavski E; Anderson AD; Miller RJ; Dein J; Giuffre AM; Tang D; Deb S; Racherla KS; Patel M; Vela MS; Puri N
Curr Top Med Chem; 2020; 20(6):458-484. PubMed ID: 31916516
[TBL] [Abstract][Full Text] [Related]
7. In perspective: An update on telomere targeting in cancer.
Sugarman ET; Zhang G; Shay JW
Mol Carcinog; 2019 Sep; 58(9):1581-1588. PubMed ID: 31062416
[TBL] [Abstract][Full Text] [Related]
8. Alternative Lengthening of Telomeres (ALT) in Tumors and Pluripotent Stem Cells.
Zhao S; Wang F; Liu L
Genes (Basel); 2019 Dec; 10(12):. PubMed ID: 31835618
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation mediated up-regulation of TERRA non-coding RNA is coincident with elongated telomeres in the human placenta.
Novakovic B; Napier CE; Vryer R; Dimitriadis E; Manuelpillai U; Sharkey A; Craig JM; Reddel RR; Saffery R
Mol Hum Reprod; 2016 Nov; 22(11):791-799. PubMed ID: 27604461
[TBL] [Abstract][Full Text] [Related]
10. Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood.
Minasi S; Baldi C; Pietsch T; Donofrio V; Pollo B; Antonelli M; Massimino M; Giangaspero F; Buttarelli FR
J Neurooncol; 2019 May; 142(3):435-444. PubMed ID: 30830680
[TBL] [Abstract][Full Text] [Related]
11. [The role of alternative lengthening of telomeres mechanisms in carcinogenesis and prospects for using an anti-telomerase drugs in malignant tumors treatment].
Grach AA
Tsitologiia; 2011; 53(10):759-71. PubMed ID: 22232932
[TBL] [Abstract][Full Text] [Related]
12. Telomere Length Maintenance in Cancer: At the Crossroad between Telomerase and Alternative Lengthening of Telomeres (ALT).
De Vitis M; Berardinelli F; Sgura A
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29463031
[TBL] [Abstract][Full Text] [Related]
13. Telomeres and telomere dynamics: relevance to cancers of the GI tract.
Basu N; Skinner HG; Litzelman K; Vanderboom R; Baichoo E; Boardman LA
Expert Rev Gastroenterol Hepatol; 2013 Nov; 7(8):733-48. PubMed ID: 24161135
[TBL] [Abstract][Full Text] [Related]
14. Alternative lengthening of telomeres can be maintained by preferential elongation of lagging strands.
Min J; Wright WE; Shay JW
Nucleic Acids Res; 2017 Mar; 45(5):2615-2628. PubMed ID: 28082393
[TBL] [Abstract][Full Text] [Related]
15. Telomere biology of pediatric cancer.
Tabori U; Dome JS
Cancer Invest; 2007; 25(3):197-208. PubMed ID: 17530490
[TBL] [Abstract][Full Text] [Related]
16. Functional Loss of
Graham MK; Kim J; Da J; Brosnan-Cashman JA; Rizzo A; Baena Del Valle JA; Chia L; Rubenstein M; Davis C; Zheng Q; Cope L; Considine M; Haffner MC; De Marzo AM; Meeker AK; Heaphy CM
Mol Cancer Res; 2019 Dec; 17(12):2480-2491. PubMed ID: 31611308
[TBL] [Abstract][Full Text] [Related]
17. A Cisplatin Derivative Tetra-Pt(bpy) as an Oncotherapeutic Agent for Targeting ALT Cancer.
Zheng XH; Nie X; Fang Y; Zhang Z; Xiao Y; Mao Z; Liu H; Ren J; Wang F; Xia L; Huang J; Zhao Y
J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 28521363
[TBL] [Abstract][Full Text] [Related]
18. Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.
Frink RE; Peyton M; Schiller JH; Gazdar AF; Shay JW; Minna JD
Oncotarget; 2016 May; 7(22):31639-51. PubMed ID: 27192120
[TBL] [Abstract][Full Text] [Related]
19. Alternative Lengthening of Telomeres in the Budding Yeast
Cohn M; Andersson AK; Mateo RQ; Möller MC
G3 (Bethesda); 2019 Oct; 9(10):3345-3358. PubMed ID: 31427453
[TBL] [Abstract][Full Text] [Related]
20. Telomere Targeting Approaches in Cancer: Beyond Length Maintenance.
Vertecchi E; Rizzo A; Salvati E
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
